Deals & business · first seen 5h ago, updated 5h ago
Fierce Pharma Asia—Lilly’s $3.35B InnoCare deal; Korea’s breakthrough; China’s 5-year biotech plan
Eli Lilly and InnoCare Pharma inked a multi-target deal potentially worth $3.35 billion. The FDA has doled out the first approval for a novel cancer drug from a Korean company. China's new pharmaceuticals five-year plan includes some ambiti…
Summary from Fierce Pharma - Pharma.